Reported by the FT and other news outlets:
“The chief executive of the biotech behind the first Covid-19 vaccine has said a new formulation is likely to be needed by the middle of next year to protect against the virus as it mutates.”
Referring to the current situation:
“Booster shots seem able to tackle the main variants, Sahin said. But the virus will eventually develop mutations that can escape the immune response bestowed by the vaccine, he said, necessitating a “tailored” version to specifically target the new strain.
“This virus will stay, and the virus will further adapt,” he said. “We have no reason to assume that the next generation virus will be easier to handle for the immune system than the existing generation. This is a continuous evolution, and that evolution has just started.”
Continuous revenue for the forseeable future.